James E. Dentzer - 17 Mar 2026 Form 4 Insider Report for CURIS INC (CRIS)

Reporting relationship: President & CEO, Director
Issuer ticker: CRIS
Reported as of: 17 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Mar 2026, 16:21:20 UTC
Prior SEC filing: 06 Jan 2026
Next SEC filing: 23 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Diantha Duvall, Attorney-in-fact

Key filing fact

James E. Dentzer filed Form 4 for CURIS INC (CRIS) on 18 Mar 2026.

Key facts

This page summarizes James E. Dentzer's Form 4 filing for CURIS INC (CRIS).
4 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 18 Mar 2026, 16:21.

Change

Previous filing in this sequence was filed on 06 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001400977 Primary reporting owner

Dentzer James E

Relationship: President & CEO, Director
Address: 128 SPRING STREET, BUILDING C - SUITE 500, LEXINGTON
Signature: /s/ Diantha Duvall, Attorney-in-fact
Signature date: 18 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRIS transaction Derivative

Series B Convertible Preferred Stock

Award

Transaction value
Shares: +100
Change %
Price
Shares after: 100
Date: 17 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100
Exercise price
Footnotes: F1, F2

CRIS transaction Derivative

Series A Warrant (right to buy)

Award

Transaction value
Shares: +133,333
Change %
Price
Shares after: 133,333
Date: 17 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 133,333
Exercise price: $0.7500
Footnotes: F2, F3

CRIS transaction Derivative

Series B Warrant (right to buy)

Award

Transaction value
Shares: +133,333
Change %
Price
Shares after: 133,333
Date: 17 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 133,333
Exercise price: $0.7500
Footnotes: F2, F4

CRIS transaction Derivative

Series C Warrant (right to buy)

Award

Transaction value
Shares: +133,333
Change %
Price
Shares after: 133,333
Date: 17 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 133,333
Exercise price: $0.7500
Footnotes: F2, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations).

Footnote F2

Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

Footnote F3

Each Series A Warrant became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series A Warrant) on March 17, 2026.

Footnote F4

The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia ("Initial Termination Date"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the "Exercise Price"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days.

Footnote F5

The Series C Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing on March 17, 2026.